Navigation Links
Chemosensitivity/Resistance Assay Included as Part of the NCCN Principles of Chemotherapy
Date:2/25/2010

PITTSBURGH, Feb. 25 /PRNewswire/ -- Precision Therapeutics announced today that The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section. While the NCCN Guidelines™ state that this technology is not intended to supplant standard of care chemotherapy, chemosensitivity/resistance assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. This is a NCCN category 3 recommendation.

Recent studies presented at ASCO and published in the International Journal of Gynecologic Cancer, evaluated the association between prediction of response to chemotherapy and progression-free interval and overall survival in ovarian cancer.

"We offer our gratitude to NCCN on behalf of the many ovarian cancer patients who could be faced with the potential side effects of ineffective chemotherapies.  Not only are oncologists recognizing the benefits of using chemosensitivity and resistance assays when faced with equivalent therapeutic options, but they are also paving the way for greater support of personalized medicine in oncology," says Karen Kaplan, CEO of the Ovarian Cancer National Alliance.  

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country's fifth most common cause of cancer mortality in women. In the year 2009, there were more than 21,000 new diagnoses and nearly 15,000 deaths from this neoplasm in the United States.

The NCCN Clinical Practice Guidelines in Oncology™ are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines™ are available free of charge at NCCN.org.

About the Ovarian Cancer National Alliance

The Ovarian Cancer National Alliance is the foremost advocate for women with ovarian cancer in the United States. To advance the interests of women with ovarian cancer, the organization advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols. The Ovarian Cancer National Alliance educates health care professionals and raises public awareness of the signs and symptoms of ovarian cancer.  For more information, visit www.ovariancancer.org.

About Precision Therapeutics

Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.

Precision's ChemoFx®, a proprietary drug response marker, measures an individual patient's tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician's experience and provide valuable patient-specific information, particularly when there is non-uniform response to standard cancer treatment or no clear choice for the next regimen.

For more information:

http://www.precisiontherapeutics.com

http://www.chemofx.com

SOURCE Precision Therapeutics

Back to top

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer Symposium
6. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
7. DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
8. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
9. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
10. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
11. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):